163 Ribonulceotide Reductase M2 (RRM2): Predictive Marker of Response to Gemcitabine in Pancreatic Cancer
Farrell J, Garcia M, Liu X, Ammar A, Regine W, Abrams R, Elsaleh H. 163 Ribonulceotide Reductase M2 (RRM2): Predictive Marker of Response to Gemcitabine in Pancreatic Cancer. Gastroenterology 2009, 136: a-32. DOI: 10.1016/s0016-5085(09)60146-3.Peer-Reviewed Original Research